JP2016509011A5 - - Google Patents

Download PDF

Info

Publication number
JP2016509011A5
JP2016509011A5 JP2015557089A JP2015557089A JP2016509011A5 JP 2016509011 A5 JP2016509011 A5 JP 2016509011A5 JP 2015557089 A JP2015557089 A JP 2015557089A JP 2015557089 A JP2015557089 A JP 2015557089A JP 2016509011 A5 JP2016509011 A5 JP 2016509011A5
Authority
JP
Japan
Prior art keywords
immunogenic composition
composition according
seq
amino acid
polysaccharide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015557089A
Other languages
English (en)
Other versions
JP2016509011A (ja
JP6494527B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/015254 external-priority patent/WO2014124228A1/en
Publication of JP2016509011A publication Critical patent/JP2016509011A/ja
Publication of JP2016509011A5 publication Critical patent/JP2016509011A5/ja
Priority to JP2019039100A priority Critical patent/JP6916828B2/ja
Application granted granted Critical
Publication of JP6494527B2 publication Critical patent/JP6494527B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

  1. (i) ビオチン結合タンパク質またはその機能的部分と;
    (ii) SEQ ID NO: 190のアミノ酸配列、または免疫原性部分、と少なくとも90%の同一性を有するポリペプチドを含む、SEQ ID NO: 34のアミノ酸配列と少なくとも90%の同一性を有するアミノ酸配列を含むポリペプチドまたはその断片と
    を含む融合タンパク質を含む、免疫原性組成物。
  2. ビオチン結合タンパク質がリザビジンである、請求項1に記載の免疫原性組成物。
  3. ポリペプチドが、SEQ ID NO: 34のアミノ酸配列、またはSEQ ID NO: 190のアミノ酸を含むSEQ ID NO: 34の免疫原性部分を含む、請求項1に記載の免疫原性組成物。
  4. ビオチン化多糖をさらに含む、請求項1〜3のいずれか一項に記載の免疫原性組成物。
  5. 多糖が、肺炎球菌多糖である、請求項4に記載の免疫原性組成物。
  6. ビオチン化多糖が、前記融合タンパク質と親和性結合体形成している、請求項4または5に記載の免疫原性組成物。
  7. アジュバントをさらに含む、請求項1〜6のいずれか一項に記載の免疫原性組成物。
  8. 医学的に使用するための、請求項1〜7のいずれか一項に記載の免疫原性組成物。
  9. 肺炎球菌感染に起因する、肺炎球菌疾患、障害、および/または状態の、処置および/または予防において使用するための、請求項1〜8のいずれか一項に記載の免疫原性組成物。
JP2015557089A 2013-02-07 2014-02-07 肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原 Active JP6494527B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019039100A JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361762062P 2013-02-07 2013-02-07
US61/762,062 2013-02-07
PCT/US2014/015254 WO2014124228A1 (en) 2013-02-07 2014-02-07 Protein antigens that provide protection against pneumococcal colonization and/or disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019039100A Division JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原

Publications (3)

Publication Number Publication Date
JP2016509011A JP2016509011A (ja) 2016-03-24
JP2016509011A5 true JP2016509011A5 (ja) 2017-03-09
JP6494527B2 JP6494527B2 (ja) 2019-04-03

Family

ID=51300148

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015557089A Active JP6494527B2 (ja) 2013-02-07 2014-02-07 肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原
JP2019039100A Active JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019039100A Active JP6916828B2 (ja) 2013-02-07 2019-03-05 肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原

Country Status (7)

Country Link
US (2) US11576958B2 (ja)
EP (2) EP2953638B1 (ja)
JP (2) JP6494527B2 (ja)
AU (2) AU2014214844B2 (ja)
CA (1) CA2900008A1 (ja)
ES (1) ES2959258T3 (ja)
WO (1) WO2014124228A1 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013028887B1 (pt) 2011-05-11 2020-10-06 Children's Medical Center Corporation Composição imunogênica apresentando múltiplos antígenos, e métodos e usos dos mesmos
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
KR102701633B1 (ko) * 2017-02-24 2024-09-02 머크 샤프 앤드 돔 엘엘씨 폐렴구균 접합체 백신 제제
CA3061709A1 (en) 2017-03-28 2018-10-04 The Children's Medical Center Corporation A multiple antigen presenting system (maps)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
US10525119B2 (en) 2017-03-31 2020-01-07 Boston Medical Center Corporation Methods and compositions using highly conserved pneumococcal surface proteins
KR20200018787A (ko) * 2017-05-22 2020-02-20 더 칠드런스 메디칼 센터 코포레이션 마이코박테리움 투버큘로시스에 대한 혼합 백신
ES2967001T3 (es) 2017-06-23 2024-04-25 Affinivax Inc Composiciones inmunogénicas
GB201807303D0 (en) * 2018-05-03 2018-06-20 London School Of Hygeine & Tropical Medicine Glyconjugate vaccines
GB201807380D0 (en) * 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
CA3111273C (en) * 2018-09-06 2024-03-26 Bavarian Nordic A/S Storage improved poxvirus compositions
US20200087361A1 (en) * 2018-09-12 2020-03-19 The Children's Medical Center Corporation Pneumococcal fusion protein vaccines
WO2020056202A1 (en) * 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
AU2021229452A1 (en) * 2020-03-03 2022-09-29 Mayo Foundation For Medical Education And Research Zika virus polypeptides
KR20220018939A (ko) * 2020-08-07 2022-02-15 (주)셀트리온 폐렴구균 다당류-세포벽 유래 물질 접합체를 포함하는 면역원성 조성물
MX2024002779A (es) 2021-09-09 2024-06-11 Affinivax Inc Vacunas neumocócicas multivalentes.
WO2024192346A1 (en) * 2023-03-16 2024-09-19 Affinivax, Inc. Immunogenic compositions

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB1502774A (en) 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
US4242501A (en) 1979-08-08 1980-12-30 American Cyanamid Company Purification of pneumococcal capsular polysaccharides
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4987237A (en) 1983-08-26 1991-01-22 Ribi Immunochem Research, Inc. Derivatives of monophosphoryl lipid A
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3779909T2 (de) 1986-03-06 1993-01-07 Commw Scient Ind Res Org In-vitro-testverfahren zum nachweis zellulaerer immunresponsen.
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8906795D0 (en) 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JPH0372423A (ja) 1989-05-26 1991-03-27 Green Cross Corp:The パーフルオロカーボン化合物含有乳化製剤
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5371197A (en) 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5674698A (en) 1992-09-14 1997-10-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
CA2215933C (en) 1995-03-22 2009-10-13 Andrew Lees Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
NZ331164A (en) 1996-02-09 2000-02-28 Univ Liege Vaccines against varicella zoster virus gene 63 product
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
DE69739981D1 (de) 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6087328A (en) 1997-04-24 2000-07-11 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6287568B1 (en) 1997-09-09 2001-09-11 The Trustees Of Columbia University In The City Of New York Methods relating to immunogenic dextran-protein conjugates
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
ATE361365T1 (de) * 1998-07-27 2007-05-15 Sanofi Pasteur Ltd Streptococcus pneumoniae proteine und nukleinsäuren
JP2002521058A (ja) * 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
GB9928678D0 (en) 1999-12-03 2000-02-02 Provalis Uk Ltd Streptococcus pneumoniae antigens
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
US7262286B2 (en) 2000-09-26 2007-08-28 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
SE0003538D0 (sv) 2000-09-29 2000-09-29 Isconova Ab New immunogenic complex
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
CA2492823A1 (en) 2001-09-14 2003-03-27 Martin F. Bachmann In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002364783A1 (en) 2001-11-21 2003-06-10 Affinium Pharmaceuticals, Inc. Purified polypeptides involved in general metabolism
EP1506007B1 (en) 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
US20060121058A1 (en) 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
KR20050086427A (ko) 2002-11-07 2005-08-30 시너지 아메리카 인코포레이티드 폐렴균의 감염 치료 또는 예방용 조성물 및 방법
AU2002952548A0 (en) 2002-11-08 2002-11-21 Cellestis Limited Diagnostic assay
WO2004083251A2 (en) 2003-03-17 2004-09-30 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
EP2311991A1 (en) 2003-04-15 2011-04-20 Intercell AG S. pneumoniae antigens
CA2524853A1 (en) 2003-05-07 2005-01-20 Aventis Pasteur, Inc. Method of enhanced immunogenicity to meningococcal vaccination
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
US20050013812A1 (en) 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
GB0318688D0 (en) 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
JP5097400B2 (ja) 2003-09-03 2012-12-12 デンドリセラピューティクス、インク. 複合ワクチン
US20050214318A1 (en) 2003-10-23 2005-09-29 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on fusion protein
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
US20050226899A1 (en) 2004-04-08 2005-10-13 Mauro Castiglioni Cosmetic mask composition
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
EP1791961B1 (en) 2004-08-18 2011-06-08 The Governors of the University of Alberta Protein production method utilizing yebf
FI20041396A0 (fi) 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
US8007806B2 (en) 2005-01-20 2011-08-30 Isconova Ab Vaccine composition comprising a fibronectin binding protein or a fibronectin binding peptide
WO2006084467A1 (en) 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
US20090148894A1 (en) 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
RU2457858C2 (ru) 2005-09-01 2012-08-10 Новартис Вэксинес Энд Дайэгностикс Гмбх Унд Ко Кг Множественная вакцинация, включающая менингококки серогруппы с
CA2632663C (en) 2005-12-08 2015-08-18 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
WO2007081583A2 (en) 2006-01-04 2007-07-19 Children's Medical Center Corporation Anti-pneumococcal preparations and methods of use
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
US20100226932A1 (en) 2006-02-22 2010-09-09 Novavax, Inc. Adjuvant and Vaccine Compositions
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
US8148084B2 (en) 2006-06-22 2012-04-03 Dana-Farber Cancer Institute, Inc. Diagnosis of autoimmune disease
EP2041175A4 (en) 2006-06-23 2011-03-16 Augmenta Biolog Llc TARGETED IMMUNOJUGATE
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
CA2663295C (en) 2006-09-12 2020-03-10 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
NZ576563A (en) 2006-11-03 2012-09-28 Alphavax Inc Alphavirus and alphavirus replicon particle formulations and methods
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
WO2008152448A2 (en) 2006-12-21 2008-12-18 Emergent Product Development Uk Limited Streptococcus proteins, and their use in vaccination
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
JP5714230B2 (ja) 2007-01-31 2015-05-07 フェネックス インコーポレイテッド 発現上昇のための細菌リーダー配列
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
WO2009023300A2 (en) 2007-04-13 2009-02-19 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
US20100183662A1 (en) 2007-06-26 2010-07-22 Ralph Leon Biemans Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20100168392A1 (en) 2007-08-10 2010-07-01 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US20090068288A1 (en) 2007-09-07 2009-03-12 Wayne Kruger Topical antiseptic veterinary solution
US9125863B2 (en) 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
JP2012512257A (ja) 2008-12-17 2012-05-31 ジェノセア バイオサイエンシーズ, インコーポレイテッド クラミジア抗原およびその使用
CN106008679A (zh) 2008-12-24 2016-10-12 荷兰王国卫生福利和运动部国家公共卫生和环境研究所 修饰的肺炎链球菌溶血素(ply)多肽
EP2208787A1 (en) 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN102458463B (zh) 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗:诱发免疫应答的组合物和方法
MX2012000158A (es) 2009-06-29 2012-06-08 Genocea Biosciences Inc Vacunas y composiciones contra streptococcus pneumoniae.
EP2485764A4 (en) 2009-10-09 2014-01-29 Childrens Medical Center WHOLE CELL VACCINE WITH SELECTIVE DISSOCIATION
EP2335721A1 (en) 2009-12-21 2011-06-22 Institut Pasteur Streptavidin and Biotin-based antigen delivery system
US20110159040A1 (en) 2009-12-30 2011-06-30 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
EP2563396A2 (en) 2010-04-30 2013-03-06 Augmenta Biologicals LLC Delivery proteins
CA2849391A1 (en) 2010-10-20 2012-04-26 Genocea Biosciences, Inc. Chlamydia antigens and uses thereof
RU2623174C2 (ru) 2011-01-20 2017-06-22 Дженоцея Байосайенсиз, Инк. Вакцины и композиции против streptococcus pneumoniae
BR112013028887B1 (pt) 2011-05-11 2020-10-06 Children's Medical Center Corporation Composição imunogênica apresentando múltiplos antígenos, e métodos e usos dos mesmos
US9765125B2 (en) 2012-01-20 2017-09-19 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against Streptococcus pneumoniae
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
EP2953638B1 (en) 2013-02-07 2023-07-05 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
TWI756893B (zh) 2015-07-21 2022-03-01 美商輝瑞股份有限公司 包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
WO2020056202A1 (en) 2018-09-12 2020-03-19 Affinivax, Inc. Multivalent pneumococcal vaccines
US20200087361A1 (en) 2018-09-12 2020-03-19 The Children's Medical Center Corporation Pneumococcal fusion protein vaccines

Similar Documents

Publication Publication Date Title
JP2016509011A5 (ja)
JP2015214545A5 (ja)
JP2017532343A5 (ja)
JP2014051497A5 (ja)
EP4306538A3 (en) Peptide oligonucleotide conjugates
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
PH12016500866A1 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2014159822A3 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
JP2012511545A5 (ja)
JP2016539946A5 (ja)
JP2015517489A5 (ja)
JP2009520758A5 (ja)
JP2012126742A5 (ja)
JP2019533722A5 (ja)
TW201613964A (en) Improved A[beta] protofibril binding antibodies
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
IN2014CN04498A (ja)
WO2013098755A3 (en) Anticancer fusion protein
JP2013501007A5 (ja)
WO2015031778A3 (en) Compositions and methods for the treatment or prevention of tuberculosis
WO2019081595A3 (en) Dpp3 binder directed to and binding to specific dpp3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress
WO2012143477A3 (en) Anticancer fusion protein
JP2016520534A5 (ja)
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
HRP20191864T1 (hr) Imunogeni pripravci protiv bakterije clostridium difficile